CD8A and neoplasm: Intriguingly, memory CD8+ T cells lacking Zbtb20 confer superior protection against tumors compared to wild-type (WT) memory cells [9], suggesting that deletion or inhibition of Zbtb20 in CD8+ T cells may provide a promising strategy for anti-tumor immunotherapy.